Pharmosa Biopharm Inc.   Report issue

For profit Phase 1 Phase 3
Founded: Taichung China (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
2018
NCT04041648
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Pharmosa Biopharm Inc. | Pharmosa Biopharm Inc.PPD

Active Ingredients

Drugs in Phase 3 Trials (1)

treprostinil (remodulin) (2 trials)

Drugs in Phase 1 Trials (1)

iloprost (ventavis) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hypertension (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2